The authors proved that these CAR-T cells effectively recognized and killed HER2+ tumor cells in vitro and significantly improved the immune response against human trastuzumab-resistant breast cancer even at very low numbers (only 7% of T cells were CAR-T cells), resulting in complete tumor remission within 57 days and a significant survival extension. Here, ERBB2 is linked to breast cancer.